- Home
- PYPD vs KZR Comparison
PYPD vs KZR Comparison
Compare PYPD & KZR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PYPD
- KZR
- Stock Information
- Founded
- PYPD 2008
- KZR 2015
- Country
- PYPD Israel
- KZR United States
- Employees
- PYPD N/A
- KZR N/A
- Industry
- PYPD Medical/Dental Instruments
- KZR Biotechnology: Pharmaceutical Preparations
- Sector
- PYPD Health Care
- KZR Health Care
- Exchange
- PYPD Nasdaq
- KZR Nasdaq
- Market Cap
- PYPD 34.8M
- KZR 29.7M
- IPO Year
- PYPD 2020
- KZR 2018
- Fundamental
- Price
- PYPD $3.37
- KZR $3.94
- Analyst Decision
- PYPD Strong Buy
- KZR Hold
- Analyst Count
- PYPD 5
- KZR 2
- Target Price
- PYPD $12.00
- KZR $9.00
- AVG Volume (30 Days)
- PYPD 71.2K
- KZR 35.3K
- Earning Date
- PYPD 08-13-2025
- KZR 08-13-2025
- Dividend Yield
- PYPD N/A
- KZR N/A
- EPS Growth
- PYPD N/A
- KZR N/A
- EPS
- PYPD N/A
- KZR N/A
- Revenue
- PYPD N/A
- KZR N/A
- Revenue This Year
- PYPD N/A
- KZR N/A
- Revenue Next Year
- PYPD N/A
- KZR N/A
- P/E Ratio
- PYPD N/A
- KZR N/A
- Revenue Growth
- PYPD N/A
- KZR N/A
- 52 Week Low
- PYPD $2.30
- KZR $3.62
- 52 Week High
- PYPD $3.93
- KZR $9.18
- Technical
- Relative Strength Index (RSI)
- PYPD 48.80
- KZR 43.17
- Support Level
- PYPD $3.35
- KZR $3.84
- Resistance Level
- PYPD $3.56
- KZR $4.10
- Average True Range (ATR)
- PYPD 0.16
- KZR 0.14
- MACD
- PYPD 0.00
- KZR 0.02
- Stochastic Oscillator
- PYPD 65.56
- KZR 32.43
About PYPD PolyPid Ltd.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.
About KZR Kezar Life Sciences Inc.
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.